IFNA1 and hepatocellular carcinoma: However, a retrospective multicenter cohort trial by Bielen et al. found that there was no difference in the rate of early occurrence of new HCC among patients treated with DAA agents without pegylated interferon (PEG-IFN), and the rate of early HCC recurrence in patients treated with DAA agents without PEG-IFN was higher than that in patients treated with PEG-IFN+DAA.